Previous Close | 0.0300 |
Open | 0.0325 |
Bid | 0.0300 x N/A |
Ask | 0.0490 x N/A |
Day's Range | 0.0325 - 0.0325 |
52 Week Range | 0.0065 - 0.0800 |
Volume | |
Avg. Volume | 542 |
Market Cap | 3.936M |
Beta (5Y Monthly) | -1.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0300 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
KELOWNA, BC / ACCESSWIRE / April 24, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) is pleased to announce that the shareholders of Exopharm Limited ACN 163 765 991 ("Exopharm") have approved the previously announced ...
KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) is pleased to announce that the Company's securityholders overwhelmingly approved the previously announced arrangement (the "Arrangement") ...
KELOWNA, BC / ACCESSWIRE / February 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of ...